After a decade of hype, Najat Khan is bringing Recursion back down to earth

Chris Gibson built the pioneering AI biotech Recursion Pharmaceuticals on a foundation of bold promises. But after more than a decade at the helm, Gibson stepped down as CEO in November 2025. Chris Gibson built the pioneering AI biotech Recursion Pharmaceuticals on a foundation of bold promises. But after more than a decade at the helm, Gibson stepped down as CEO in November 2025. And his replacement, Najat Khan, Ph.D., is laser-focused on one thing: turning the amorphous potential of AI into tangible products for patients. Biotech Cell & Gene Therapy Clinical Data Venture Capital Deals Research Medtech Devices…

Source: FierceBiotech